5.31
0.21 (4.12%)
| Previous Close | 5.10 |
| Open | 5.26 |
| Volume | 1,896,178 |
| Avg. Volume (3M) | 2,962,593 |
| Market Cap | 480,769,024 |
| Price / Earnings (Forward) | 29.41 |
| Price / Sales | 0.170 |
| Price / Book | 0.530 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -29.43% |
| Operating Margin (TTM) | -3.81% |
| Diluted EPS (TTM) | -8.39 |
| Quarterly Revenue Growth (YOY) | -1.60% |
| Total Debt/Equity (MRQ) | 149.92% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 164.20 M |
| Levered Free Cash Flow (TTM) | 310.66 M |
| Return on Assets (TTM) | -1.74% |
| Return on Equity (TTM) | -61.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Fortrea Holdings Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 101.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Mizuho, 31.83%) | Hold |
| Median | 5.00 (-5.84%) | |
| Low | 5.00 (Goldman Sachs, -5.84%) | Hold |
| 5.00 (Evercore ISI Group, -5.84%) | Hold | |
| 5.00 (Barclays, -5.84%) | Sell | |
| Average | 5.50 (3.58%) | |
| Total | 3 Hold, 1 Sell | |
| Avg. Price @ Call | 4.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 11 Jul 2025 | 7.00 (31.83%) | Hold | 5.11 |
| 14 May 2025 | 8.00 (50.66%) | Hold | 4.78 | |
| Evercore ISI Group | 09 Jul 2025 | 5.00 (-5.84%) | Hold | 5.04 |
| Goldman Sachs | 14 May 2025 | 5.00 (-5.84%) | Hold | 4.78 |
| Barclays | 13 May 2025 | 5.00 (-5.84%) | Sell | 5.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jul 2025 | Announcement | Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call |
| 24 Jun 2025 | Announcement | Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin |
| 12 Jun 2025 | Announcement | Fortrea Adopts Limited-Duration Stockholder Rights Plan |
| 11 Jun 2025 | Announcement | Fortrea Names Anshul Thakral Chief Executive Officer |
| 03 Jun 2025 | Announcement | Fortrea to Present at the Jefferies Global Healthcare Conference |
| 12 May 2025 | Announcement | Fortrea Reports First Quarter 2025 Results |
| 12 May 2025 | Announcement | Fortrea Announces CEO Stepping Down |
| 01 May 2025 | Announcement | Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |